Champions Oncology director reports stock options
Champions Oncology, Inc. director Robert Lawrence Brainin filed an initial ownership report showing a stock option holding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Champions Oncology, Inc. director Robert Lawrence Brainin filed an initial ownership report showing a stock option holding. He holds an option to purchase 8,032 shares of common stock at an exercise price of $9.27 per share, expiring on June 9, 2031. The option vests over a two‑month period, with 6,024 options vesting on June 9, 2021 and 2,008 options vesting on August 9, 2021, and is held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Option to purchase Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The options vest and are exercisable over a two month period, with vesting for 6,024 options to occur on June 9, 2021 and 2,008 options to occur on August 9, 2021.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position did Robert Lawrence Brainin report at Champions Oncology (CSBR)?
What are the key terms of the stock option reported by the Champions Oncology (CSBR) director?
How does the stock option for the Champions Oncology (CSBR) director vest?
Is the reported Champions Oncology (CSBR) stock option held directly or indirectly?
What type of SEC form did the Champions Oncology (CSBR) director file?
AI-generated analysis. How Rhea-AI works. Not financial advice.